{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T13:13:19Z","timestamp":1795093999840,"version":"4.10.2"},"reference-count":69,"publisher":"Oxford University Press (OUP)","issue":"42","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Endowed Chair in Cardiology"},{"name":"Hassenfeld Scholar Award"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL130539"],"award-info":[{"award-number":["R01HL130539"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL137562"],"award-info":[{"award-number":["R01HL137562"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["K24HL150238"],"award-info":[{"award-number":["K24HL150238"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL159187"],"award-info":[{"award-number":["R01HL159187"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Over the last decade or so, there has been a paradigm shift in the oncologic care of patients with a range of solid tumour and haematologic malignancies, away from traditional cytotoxic chemotherapy and towards personalized cancer treatments, using both targeted therapy and immunotherapy. This shift has contributed to the remarkable and sustained increase in the number of cancer survivors and the longevity of patients with a cancer diagnosis. This review will focus on the cardiovascular effects of immune checkpoint inhibitors and will present a background on immune checkpoint inhibition for cancer, the epidemiology, potential mechanisms, the potential insights into cardiovascular biology, and a diagnostic and therapeutic approach to potential cases. Our understanding of the cardiovascular effects of immune checkpoint inhibitors needs to improve. However, the evolution necessarily needs to be rapid. Initial observations noted that immune checkpoint inhibitor therapy can lead to a fulminant myocarditis. Recent reports have expanded the effect of immune checkpoint inhibitor therapy on the cardiovascular system to include an increase in cardiac dysfunction without myocarditis, arrhythmias, venous thromboembolic disease, accelerated atherosclerosis, and atherosclerosis-related cardiovascular events. The association between immune checkpoint inhibitor therapy and an increase in these cardiovascular events is not only limited to events occurring within the first few weeks after starting therapy but can also include events that occur months to years after therapy. The latter observation is especially of relevance in those treated with adjuvant or neoadjuvant therapy. There needs to be a shift from recognition of an increase in cardiovascular events to currently approved immune checkpoint inhibitor therapies to understanding the mechanisms that lead to adverse cardiovascular effects, understanding who is at risk, and understanding what we can do about it.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehac456","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T09:22:09Z","timestamp":1661332929000},"page":"4458-4468","source":"Crossref","is-referenced-by-count":136,"title":["Cardiovascular complications of immune checkpoint inhibitors for cancer"],"prefix":"10.1093","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8727-7154","authenticated-orcid":false,"given":"Franck","family":"Thuny","sequence":"first","affiliation":[{"name":"Aix-Marseille University, University Mediterranean Center of Cardio-Oncology, Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, North Hospital, Assistance Publique - H\u00f4pitaux de Marseille, Centre for CardioVascular and Nutrition Research (C2VN), Inserm 1263, Inrae 1260 , Marseille , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3470-8686","authenticated-orcid":false,"given":"Jarushka","family":"Naidoo","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, John Hopkins University , Baltimore, MD , USA"},{"name":"Beaumont Hospital and RCSI University of Health Sciences , Dublin , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1513-8833","authenticated-orcid":false,"given":"Tomas G","family":"Neilan","sequence":"additional","affiliation":[{"name":"Division of Cardiology and Department of Radiology, Cardiovascular Imaging Research Center (CIRC), Massachusetts General Hospital , Boston, MA , USA"},{"name":"Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"2023063004532939400_ehac456-B1","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3389\/fimmu.2019.02965","article-title":"The intriguing history of cancer immunotherapy","volume":"10","author":"Dobosz","year":"2019","journal-title":"Front Immunol"},{"key":"2023063004532939400_ehac456-B2","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"2023063004532939400_ehac456-B3","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"2023063004532939400_ehac456-B4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2023063004532939400_ehac456-B5","doi-asserted-by":"crossref","first-page":"6446","DOI":"10.1158\/1078-0432.CCR-09-1339","article-title":"Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma","volume":"15","author":"Ansell","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2023063004532939400_ehac456-B6","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"2023063004532939400_ehac456-B7","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41573-021-00345-8","article-title":"The foundations of immune checkpoint blockade and the ipilimumab approval decennial","volume":"21","author":"Korman","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"2023063004532939400_ehac456-B8","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","article-title":"Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes","volume":"8","author":"Agata","year":"1996","journal-title":"Int Immunol"},{"key":"2023063004532939400_ehac456-B9","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023063004532939400_ehac456-B10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/intimm\/dxh194","article-title":"PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells","volume":"17","author":"Iwai","year":"2004","journal-title":"Int Immunol"},{"key":"2023063004532939400_ehac456-B11","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"2023063004532939400_ehac456-B12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaccao.2020.11.012","article-title":"The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity: JACC: CardioOncology primer","volume":"3","author":"Zhang","year":"2021","journal-title":"JACC CardioOncol"},{"key":"2023063004532939400_ehac456-B13","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"2023063004532939400_ehac456-B14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2023063004532939400_ehac456-B15","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"2023063004532939400_ehac456-B16","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"2023063004532939400_ehac456-B17","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"2023063004532939400_ehac456-B18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaccao.2021.01.004","article-title":"Myocarditis surveillance with high-sensitivity troponin I during cancer treatment with immune checkpoint inhibitors","volume":"3","author":"Waliany","year":"2021","journal-title":"JACC CardioOncol"},{"key":"2023063004532939400_ehac456-B19","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2023063004532939400_ehac456-B20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"2023063004532939400_ehac456-B21","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"key":"2023063004532939400_ehac456-B22","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"2023063004532939400_ehac456-B23","doi-asserted-by":"crossref","first-page":"e002771","DOI":"10.1136\/jitc-2021-002771","article-title":"Pericardial disease in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gong","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2023063004532939400_ehac456-B24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2021.09.010","article-title":"Immune checkpoint inhibitors for cancer and venous thromboembolic events","volume":"158","author":"Gong","year":"2021","journal-title":"Eur J Cancer"},{"key":"2023063004532939400_ehac456-B25","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"2023063004532939400_ehac456-B26","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/ejhf.1497","article-title":"Takotsubo syndrome in patients with cancer treated with immune checkpoint inhibitors: a new adverse cardiac complication","volume":"21","author":"Ederhy","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2023063004532939400_ehac456-B27","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/eurheartj\/ehaa884","article-title":"The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study","volume":"42","author":"D'Souza","year":"2021","journal-title":"Eur Heart J"},{"key":"2023063004532939400_ehac456-B28","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.cjca.2019.11.035","article-title":"Acute coronary syndrome with immune checkpoint inhibitors: a proof-of-concept case and pharmacovigilance analysis of a life-threatening adverse event","volume":"36","author":"Cautela","year":"2020","journal-title":"Can J Cardiol"},{"key":"2023063004532939400_ehac456-B29","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/ejhf.2289","article-title":"Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis","volume":"23","author":"Rubio-Infante","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2023063004532939400_ehac456-B30","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.jacc.2017.08.050","article-title":"Prognostic value of cardiac magnetic resonance tissue characterization in risk stratifying patients with suspected myocarditis","volume":"70","author":"Grani","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2023063004532939400_ehac456-B31","doi-asserted-by":"crossref","first-page":"e000261","DOI":"10.1136\/jitc-2019-000261","article-title":"Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors","volume":"8","author":"Dolladille","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2023063004532939400_ehac456-B32","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","article-title":"Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis","volume":"75","author":"Awadalla","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2023063004532939400_ehac456-B33","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"key":"2023063004532939400_ehac456-B34","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1148\/radiol.211765","article-title":"Cardiac MRI features and prognostic value in immune checkpoint inhibitor-induced myocarditis","volume":"303","author":"Cadour","year":"2022","journal-title":"Radiology"},{"key":"2023063004532939400_ehac456-B35","doi-asserted-by":"crossref","first-page":"e002007","DOI":"10.1136\/jitc-2020-002007","article-title":"Electrocardiographic features of immune checkpoint inhibitor associated myocarditis","volume":"9","author":"Zlotoff","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2023063004532939400_ehac456-B36","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jacc.2021.01.050","article-title":"Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint inhibitor-associated myocarditis","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2023063004532939400_ehac456-B37","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation"},{"key":"2023063004532939400_ehac456-B38","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","article-title":"Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis","volume":"41","author":"Zhang","year":"2020","journal-title":"Eur Heart J"},{"key":"2023063004532939400_ehac456-B39","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/ejhf.2265","article-title":"Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy","volume":"23","author":"Palaskas","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2023063004532939400_ehac456-B40","doi-asserted-by":"crossref","first-page":"e018306","DOI":"10.1161\/JAHA.120.018306","article-title":"Decreased absolute lymphocyte count and increased neutrophil\/lymphocyte ratio with immune checkpoint inhibitor-associated myocarditis","volume":"9","author":"Drobni","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2023063004532939400_ehac456-B41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41379-019-0363-0","article-title":"Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms","volume":"33","author":"Champion","year":"2020","journal-title":"Mod Pathol"},{"key":"2023063004532939400_ehac456-B42","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1161\/CIRCULATIONAHA.121.055816","article-title":"Electrocardiographic manifestations of immune checkpoint inhibitor myocarditis","volume":"144","author":"Power","year":"2021","journal-title":"Circulation"},{"key":"2023063004532939400_ehac456-B43","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors-a systematic review","volume":"37","author":"Daxini","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2023063004532939400_ehac456-B44","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1161\/CIRCRESAHA.120.315894","article-title":"Mechanisms of cardiovascular toxicities associated with immunotherapies","volume":"128","author":"Baik","year":"2021","journal-title":"Circ Res"},{"key":"2023063004532939400_ehac456-B45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2013.05.004","article-title":"The heart of the matter: protection of the myocardium from T cells","volume":"45","author":"Lichtman","year":"2013","journal-title":"J Autoimmun"},{"key":"2023063004532939400_ehac456-B46","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/s41591-019-0590-4","article-title":"Single-cell immune landscape of human atherosclerotic plaques","volume":"25","author":"Fernandez","year":"2019","journal-title":"Nat Med"},{"key":"2023063004532939400_ehac456-B47","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"2023063004532939400_ehac456-B48","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1158\/2159-8290.CD-20-0856","article-title":"A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention","volume":"11","author":"Wei","year":"2021","journal-title":"Cancer Discov"},{"key":"2023063004532939400_ehac456-B49","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1172\/JCI31344","article-title":"Proatherogenic immune responses are regulated by the PD-1\/PD-L pathway in mice","volume":"117","author":"Gotsman","year":"2007","journal-title":"J Clin Investig"},{"key":"2023063004532939400_ehac456-B50","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/ATVBAHA.111.224709","article-title":"Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation","volume":"31","author":"Bu","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023063004532939400_ehac456-B51","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.3390\/cells9091987","article-title":"Antibody-mediated inhibition of CTLA4 aggravates atherosclerotic plaque inflammation and progression in hyperlipidemic mice","volume":"9","author":"Poels","year":"2020","journal-title":"Cells"},{"key":"2023063004532939400_ehac456-B52","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"key":"2023063004532939400_ehac456-B53","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/nature18935","article-title":"CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis","volume":"536","author":"Kojima","year":"2016","journal-title":"Nature"},{"key":"2023063004532939400_ehac456-B54","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1056\/NEJMc2029834","article-title":"Effect of CD47 blockade on vascular inflammation","volume":"384","author":"Jarr","year":"2021","journal-title":"N Engl J Med"},{"key":"2023063004532939400_ehac456-B55","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/eurheartj\/ehab430","article-title":"Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy","volume":"43","author":"Michel","year":"2022","journal-title":"Eur Heart J"},{"key":"2023063004532939400_ehac456-B56","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jaccao.2020.12.001","article-title":"Management of immune checkpoint inhibitor-induced myocarditis: the French Working Group's Plea for a pragmatic approach","volume":"3","author":"Thuny","year":"2021","journal-title":"JACC CardioOncol"},{"key":"2023063004532939400_ehac456-B57","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"key":"2023063004532939400_ehac456-B58","doi-asserted-by":"crossref","first-page":"e002553","DOI":"10.1136\/jitc-2021-002553","article-title":"Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis","volume":"9","author":"Puzanov","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2023063004532939400_ehac456-B59","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2014-206812","article-title":"Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity","volume":"74","author":"Hughes","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2023063004532939400_ehac456-B60","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","article-title":"Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations","volume":"72","author":"Ferreira","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2023063004532939400_ehac456-B61","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.acvd.2021.12.001","article-title":"18F-fluorodeoxyglucose positron emission tomography\/computed tomography imaging for the diagnosis of immune checkpoint inhibitor-associated myocarditis","volume":"115","author":"Ederhy","year":"2022","journal-title":"Arch Cardiovasc Dis"},{"key":"2023063004532939400_ehac456-B62","doi-asserted-by":"crossref","first-page":"614997","DOI":"10.3389\/fcvm.2021.614997","article-title":"Early detection of checkpoint inhibitor-associated myocarditis using 68Ga-FAPI PET\/CT","volume":"8","author":"Finke","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2023063004532939400_ehac456-B63","doi-asserted-by":"crossref","first-page":"e003594","DOI":"10.1136\/jitc-2021-003594","article-title":"68Ga-DOTATOC PET\/CT to detect immune checkpoint inhibitor-related myocarditis","volume":"9","author":"Boughdad","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2023063004532939400_ehac456-B64","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1093\/eurheartj\/ehm456","article-title":"The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology","volume":"28","author":"Cooper","year":"2007","journal-title":"Eur Heart J"},{"key":"2023063004532939400_ehac456-B65","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2023063004532939400_ehac456-B66","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"2023063004532939400_ehac456-B67","doi-asserted-by":"crossref","first-page":"770631","DOI":"10.3389\/fphar.2021.770631","article-title":"Case series of steroid-resistant immune checkpoint inhibitor associated myocarditis: as comparative analysis of corticosteroid and tofacitinib treatment","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"2023063004532939400_ehac456-B68","doi-asserted-by":"crossref","first-page":"e001887","DOI":"10.1136\/jitc-2020-001887","article-title":"Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis","volume":"8","author":"Cautela","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2023063004532939400_ehac456-B69","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1200\/JCO.21.01806","article-title":"Prospective cardiovascular surveillance of immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell cancer: data from the phase III JAVELIN renal 101 trial","volume":"40","author":"Rini","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/42\/4458\/50738819\/ehac456.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/42\/4458\/50738819\/ehac456.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:55:51Z","timestamp":1688086551000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/43\/42\/4458\/6679177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":69,"journal-issue":{"issue":"42","published-online":{"date-parts":[[2022,8,30]]},"published-print":{"date-parts":[[2022,11,7]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehac456","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,7]]},"published":{"date-parts":[[2022,8,30]]}}}